RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its third quarter 2020 financial results before the open of the U.S. financial markets on Thursday, November 5, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Read more here:
BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

Read more from the original source:
Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

LAKE FOREST, Ill., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third quarter 2020 financial results will be released on Friday, November 6, 2020. Following the announcement, Assertio’s management team will host a live webcast at 8:30 a.m. Eastern Time to review the Company’s financial and operating results, and provide a general business update.

Read more from the original source:
Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomized Phase II clinical trial evaluating its lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalized patients with COVID-19. The necessary approvals from the Czech Republic’s State Institute for Drug Control (SUKL- competent authority) and ethics committee have now been obtained, enabling the recruitment of patients to commence immediately. Initial interim results are expected to be reported from early 2021.

See the article here:
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon PTH for the treatment of hypoparathyroidism (HP).

Read the original:
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Orphazyme A/SCompany announcement                                                                                       No. 67/2020                                                                                                          Company Registration No. 32266355

Read the original:
Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), announces the availability of a broadcast titled “Banking on the Next Blockbuster Drug.”

Continued here:
Innovative Companies with Blockbuster Potential Catch SPAC Attention

TORONTO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2020 Third Quarter Earnings Conference Call on Thursday, November 5, 2020 at 8:30 a.m. EST. Cronos Group’s senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

More here:
Cronos Group Inc. to Hold 2020 Third Quarter Earnings Conference Call on November 5, 2020

-Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-

Read this article:
Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting

PRESS RELEASE

Read more:
Bulletin from the extraordinary general meeting on October 23, 2020 in Saniona AB

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M.D. as Senior Vice President & Chief Medical Officer (CMO). Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care. He has management experience in both academic research and clinical and pharmaceutical settings. As CMO, he will be responsible for advancing Cyclacel’s pipeline and will lead clinical strategy, patient safety, and medical affairs.

See original here:
Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

Interim data on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures

See the original post here:
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer

VANCOUVER, British Columbia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”) announces that it has applied for a voluntary management cease trade order in accordance with National Policy 12-203 due to it not being able to file its annual financial statements and MD&A for the year ended June 30, 2020 on SEDAR within 120 days of its financial year-end.

Follow this link:
EXMceuticals Announces Application for Voluntary Management Cease Trade Order

CALGARY, Alberta, Oct. 23, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s 2020 Annual and Special Meeting of Shareholders held today. A total of 38,978,193 common shares of the Company were voted at the Meeting, representing approximately 48% of the total number of issued and outstanding shares. At the meeting, all five director nominees, Dr. Allen Davidoff, Ian Klassen, Bruce Rowlands, Paul Van Damme and Allan Williams, were elected as directors of the Company. In addition, at the Meeting, shareholders voted to re-appoint Morgan & Company LLP as auditors of the Company and disinterested (non-insider) shareholders also approved the Company’s 10% rolling stock option plan.

See the original post:
XORTX Reports Annual & Special Meeting Results

WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated small cell lung cancer (SCLC). The results are being featured today in a late-breaking poster presentation entitled, “Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with Dual MDM2/MDMX Inhibitor ALRN-6924” (online here) at the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics.

More here:
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the...

Company announcement no. 41 – 20 22 October 2020

Continued here:
Update on current trading for Q3 2020 and updated full-year outlook for 2020

Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

Original post:
Retrophin Announces Agreement to Acquire Orphan Technologies

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights.

Read more from the original source:
Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Leuven, Belgium - October 22, 2020 - 6.45 PM CET, ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative immune-oncology treatments, today presents its strategy directed at boosting T cell migration, infiltration and activity into solid tumors, and announces that it has reached preclinical proof of concept and has entered the lead optimization phase with its proprietary CCR8 Treg program.

Visit link:
ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary...

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient cancers This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient cancers

Read the original:
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors